Table 3.
GeneXpert Mycobacterium tuberculosis/rifampicin machines’ utilization rate stratified by the type and level of health-care facilities
| Category | GeneXpert machine, n (%) | Current utilization, n (%) | Expected utilization†, n (%) | Utilization rate≠ | P |
|---|---|---|---|---|---|
| Total | 366 | 354,321 | 1,054,080 | 33.6 | |
| Type of health facility | |||||
| Public | 318 (86.9) | 304,844 (86.0) | 915,840 (86.9) | 33.3 | <0.01 |
| Private | 48 (13.1) | 49,477 (14.0) | 138,240 (13.1) | 35.8 | |
| Type of health facility | |||||
| Primary | 23 (6.3) | 26,584 (7.5) | 66,240 (6.3) | 40.1 | <0.01 |
| Secondary | 287 (78.4) | 265,183 (74.8) | 826,560 (78.4) | 32.1 | |
| Tertiary | 56 (15.3) | 62,554 (17.7) | 161,280 (15.3) | 38.8 | <0.01 |
†Expected utilization – 4 test × 3 rounds × 5 days a week × 48 weeks; ≠Utilization rate – Total test performed/expected number of test × 100; P<0.05